Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inferring and evaluating network medicine-based disease modules with nextflow.

Bioinformatics (Oxford, England)·2026
Same author

Aberrant splicing in human cancer shows possible functional impact on transcription factors.

Oncogene·2026
Same author

An Integrated Skin Cell Atlas Decodes the Pilosebaceous Unit.

The Journal of investigative dermatology·2026
Same author

Phenotypic similarity of adverse drug reactions and disease phenotypes is a bridge to mechanistic discovery.

npj drug discovery·2026
Same author

Origin of sexual dimorphism in osteoarthritis risk: the impact of pregnancy and parental care.

BMC public health·2026
Same author

Epigallocatechin Gallate as a State-Dependent Modulator of Amyloid-<i>β</i>: Molecular Simulation-Guided Mechanistic Synthesis for Structure-Based Inhibitor Design.

Biomolecules·2026

Related Experiment Video

Updated: May 11, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

Drug Repurposing for Kala-Azar.

Biljana Arsić1,2, Budimir S Ilić3, Andreas Maier2

  • 1Department of Chemistry, Faculty of Sciences and Mathematics, University of Niš, Višegradska 33, 18000 Niš, Serbia.

Pharmaceutics
|August 28, 2025
PubMed
Summary
This summary is machine-generated.

This study explored drug repurposing for visceral leishmaniasis (VL), identifying entecavir, valganciclovir, and nifuroxazide as promising candidates. These drugs target both the parasite and host pathways, offering a novel therapeutic strategy for this neglected tropical disease.

Keywords:
PTR1Rab5aSTAT3 pathwaydrug repurposingentecavirmolecular dockingmolecular dynamics simulationnifuroxazidevalganciclovirvisceral leishmaniasis

More Related Videos

Protocols for Testing the Toxicity of Novel Insecticidal Chemistries to Mosquitoes
09:32

Protocols for Testing the Toxicity of Novel Insecticidal Chemistries to Mosquitoes

Published on: February 13, 2019

15.8K
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.5K

Related Experiment Videos

Last Updated: May 11, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
Protocols for Testing the Toxicity of Novel Insecticidal Chemistries to Mosquitoes
09:32

Protocols for Testing the Toxicity of Novel Insecticidal Chemistries to Mosquitoes

Published on: February 13, 2019

15.8K
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.5K

Area of Science:

  • Computational drug discovery
  • Parasitology
  • Pharmacology

Background:

  • Visceral leishmaniasis (VL) poses a significant global health challenge due to limitations of current treatments, including toxicity and efficacy issues.
  • Existing therapies for VL often lead to immunosuppressive complications, necessitating the development of safer and more effective treatment options.
  • There is a critical need for novel therapeutic strategies that target both the parasite and host factors involved in VL pathogenesis.

Purpose of the Study:

  • To identify and characterize repurposed drugs for visceral leishmaniasis (VL) by targeting both parasite-specific and host-associated mechanisms.
  • To employ complementary in silico drug repurposing strategies, including EIIP screening, molecular docking, and network-based analysis.
  • To validate potential drug candidates through molecular dynamics simulations and assess their pharmacokinetic properties.

Main Methods:

  • Electron-ion interaction potential (EIIP) screening and molecular docking targeting *Leishmania donovani* Rab5a and pteridine reductase 1 (PTR1).
  • Network-based drug repurposing using the Drugst.One platform, focusing on STAT3-associated gene networks.
  • Molecular dynamics (MD) simulations for complex validation and ADMET profiling for pharmacokinetic assessment.

Main Results:

  • Entecavir and valganciclovir demonstrated strong binding affinity to *L. donovani* Rab5a and PTR1, respectively, indicating repurposing potential.
  • Network analysis identified nifuroxazide as a top candidate targeting the host JAK2/TYK2-STAT3 axis, with high stability confirmed by MD simulations.
  • Nifuroxazide exhibited favorable ADMET profiles, including good oral bioavailability and membrane permeability, with no PAINS alerts.

Conclusions:

  • Guanine analogs (entecavir, valganciclovir) and the nitrofuran derivative nifuroxazide show promise as multi-target drug repurposing candidates for VL.
  • These candidates offer a dual therapeutic strategy by targeting parasite biology and host immunoregulation.
  • Further preclinical investigations are warranted to evaluate the efficacy and safety of these repurposed drugs for VL treatment.